Parenteral nutrition is often used in critically ill patients when enteral nutrition is not suffi cient or is not fully installed. Lipid emulsions are an integral part of parenteral nutrition as they off er a high caloric density and prevent the fatty liver degeneration of long-term carbohydrate-based parenteral nutrition. Beyond use as a caloric source, lipids may infl u ence the immune response. Th e standard lipid emul sion is based on soy bean oil (SO) supplying n-6 poly unsaturated fatty acids thought necessary to prevent essential fatty acid defi ciency. In critically ill patients and in animal models, however, a negative impact of these lipid emul sions has been described. Barbosa and colleagues now report the eff ects of a new lipid emulsion on clinical and experimental parameters in patients with systemic infl ammatory response syndrome and sepsis [1] . How do these eff ects integrate into our current concepts?
Use of SO-based lipid emulsions increases availability of free arachidonic acid, the precursor fatty acid of lipid mediators in septic patients [2] . A deterioration of the PaO 2 /FiO 2 ratio has been attributed to fast infusion (6 hours) instead of slow infusion (24 hours) of a SObased lipid emulsion in patients with acute respiratory distress syndrome due to generation of arachidonic acidderived prostaglandins and thromboxane [3] . In a simplifi ed model, sepsis may be described as starting with a hyperinfl ammatory phase followed by a phase of immune suppression. When used early in septic patients, SO-based lipid emulsions have been shown to increase ex vivo cytokine generation in a small study [2] . Th ese lipid emulsions also led to an increased apoptosis of splenic lymphocytes in a murine model, amplifying this key feature of immune suppres sion in late sepsis [4] . Recent European Society for Parenteral and Enteral Nutrition guidelines recommend using other available lipid emulsions with a reduced content of n-6 polyunsaturated fatty acids instead of SO-based lipid emulsions [5] .
Addition of a pure fi sh oil (FO)-based emulsion to a non-FO-containing emulsion or use of FO-containing lipid emulsions may off er alternative options to provide lipids. With this approach a supply of n-3 fatty acids may be combined with a reduced deliverance of n-6 lipids. Interestingly, the recently discovered n-3 fatty acidderived resolvins and protectins are key mediators for the active resolution of infl am matory processes and their application has shown improved outcome in a murine model of abdominal sepsis [6] . Results from smaller trials and multicenter trials including FO in the parenteral nutrition in patients after major surgery herald a good clinical benefi t, including a reduced length of stay (for example, [7] ).
A larger single-centre trial in 166 critically ill patients comparing a lipid emulsion based on SO and mediumchain triglycerides (LCT/MCT) versus the same emulsion supplemented with FO, however, failed to detect a clinical benefi t [8] . Th is study was planned to detect a faster reduction in biomarkers modeled after the time course in postoperative patients; however, the authors failed to prove a signifi cant reduction in both
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Th is study is contrasted by the recent trial of Barbosa and coworkers [1] . Th ey randomized 25 patients with systemic infl ammatory response syndrome and sepsis to receive parenteral nutrition with a LCT/MCT emulsion or a LCT/MCT/FO lipid emulsion supplied continuously over 5 days, demonstrating a highly signifi cant faster reduction in IL-6 in plasma in the LCT/MCT/FO group. In contrast to a previous study by Friesecke and colleagues [8] , the patients had a higher mortality rate and were included earlier, exhibiting high IL-6 plasma concentrations at study entry. Barbosa and colleagues could also show a signifi cantly faster improvement of the oxygenation parameter, as determined by the PaO 2 /FiO 2 ratio in the LCT/MCT/FO group. While other clinical outcome parameters were not diff erent between the two groups, a trend for a shorter length of stay in hospital was found.
Keeping in mind the small number of patients included, the interesting data of the study are supported by another small trial in 40 critically ill patients with severe acute pancreatitis [9] . In a double-blind randomized study, 5 days of parenteral nutrition using a SO-based lipid emulsion was compared with SO (80% of the lipid component) with additional FO early in the course of the disease. Th e authors reported a signifi cant reduced need for renal replacement therapy and a faster improvement in the PaO 2 /FiO 2 ratio in the SO/FO group. Furthermore, improved liver function was reported in critically ill patients when including a fraction of FO in the parenteral nutrition [10] , and parenteral nutrition-associated liver disease was reversed in a cohort of children receiving long-term parenteral nutrition when exchanging a SObased lipid emulsion for a FO-based lipid emulsion [11] .
What may we conclude from the available data? It seems prudent to use lipid emulsions with a reduced fraction of n-6 polyunsaturated fatty acids as recommended by the European Society for Parenteral and Enteral Nutrition [5] . Th e eff ect of FO seems best when used early in critically ill patients. Most studies used between 0.1 and 0.2 g/kg/day FO as part of the parenteral nutrition. Th is assumption is supported by the analysis of a database in 661 critically ill patients, including patients with sepsis, where best outcome data were found in this dose range [12] . Th e promising data from Barbosa and colleagues in septic patients should lead to trials examining the eff ects of FO in larger cohorts of patients. Abbreviations FO, fi sh oil; IL, interleukin; LCT, long-chain triglycerides; MCT, medium-chain triglycerides; PaO 2 /FiO 2 , partial pressure of arterial oxygen/fraction of inspired oxygen; SO, soy bean oil.
